<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03101514</url>
  </required_header>
  <id_info>
    <org_study_id>201708</org_study_id>
    <nct_id>NCT03101514</nct_id>
  </id_info>
  <brief_title>Kanglaite Reduce the Toxicity of Radiotherapy of Head and Neck Cancer Phase II Study</brief_title>
  <official_title>Kanglaite Reduce the Toxicity of Radiotherapy of Head and Neck Cancer Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital of Harbin Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      About 89%-100% patients with head and neck malignant tumors have radiation mucositis during&#xD;
      their radiotherapy. Until now, there is no effective method to prevent mucositis. Steroid&#xD;
      hormone, pain-relief, anti-inflammatory and other symptom-relief treatments usually are used&#xD;
      after the emergence of mucositis. Coixenol triglyceride is an ester extract of Coix Seed. Its&#xD;
      trade name is Kanglaite Injection, which has been approved in China and Russia. Kanglaite has&#xD;
      anti-tumor effect and reduce treatment toxicity of tumor. Kanglaite could also improve the&#xD;
      quality of life of patients and mitigate the condition of the cachexia. In china, two studies&#xD;
      evaluating treatment of Kanglaite to nasopharyngeal cancer, found that Kanglaite can reduce&#xD;
      radiotherapy mucositis. So far, Kanglaite on the prevention and treatment of radiation&#xD;
      mucositis of the head and neck malignant tumor is still lack of strong clinical trial&#xD;
      evidence. This is a phase II, single center, one arm study with subject to evaluate the acute&#xD;
      radiation mucositis, nutritional status, and quality of life on the course of radiotherapy of&#xD;
      head and neck cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      3-4 grade radiation mucositis account for 34%-56% in all head and neck patients treated by&#xD;
      radiotherapy and &gt;50% in patients treated by radiotherapy concurrent with chemotherapy. 3-4&#xD;
      grade radiation mucositis have obvious symptoms, presenting with fusion ulcers, ulcers&#xD;
      bleeding or obvious pain need analgesic drugs. At this time, the patients can not eat or can&#xD;
      only intake fluid diet, which led to weight loss, malnutrition, quality of life declined and&#xD;
      a series of problems.&#xD;
&#xD;
      Kanglaite has anti-tumor effect and reduce treatment toxicity of tumor. Kanglaite can reduce&#xD;
      radiotherapy mucositis of nasopharyngeal cancer had been found initially in Chinese.&#xD;
      Kanglaite on the prevention and treatment of radiation mucositis of the head and neck&#xD;
      malignant tumor is still lack of strong clinical trial evidence. This is a phase II, single&#xD;
      center, one arm study with subject to evaluation the acute radiation mucositis, nutritional&#xD;
      status, and quality of life on the course of radiotherapy of head and neck malignant tumors.&#xD;
&#xD;
      Kanglaite 200ml is injected intravenous from the first day to the last day of radiotherapy.&#xD;
      Chemotherapy with cisplatin or nedaplatin (both 80-100mg/m2, 21 day per cycle, 1-3 cycles) is&#xD;
      used or not concurrent with radiotherapy. There is no order of Kanglaite injection and&#xD;
      radiotherapy. Granulocyte colony stimulating factor and antibiotics have no prophylactic use,&#xD;
      but can be used after the decline of white blood cells. Mucositis, nutritional status, and&#xD;
      quality of life are evaluated before radiotherapy, every week of radiotherapy, 4 weeks after&#xD;
      radiotherapy. Mucositis is verified by physical examination. Nutritional status is evaluated&#xD;
      by patient-generated subjective global assessment (PG-SGA) scale. Quality of life is&#xD;
      evaluated by EORTC QLQ-C30 and QLQ-H&amp;N35 questionnaire.&#xD;
&#xD;
      This is a one arm study, sample size calculation based on the incidence of 3-4 degree&#xD;
      mucositis. The incidence of 3-4 degree mucositis is about &gt;50% according to literatures of&#xD;
      head and neck squamous cell carcinoma intensity modulated radiation therapy concurrent with&#xD;
      chemotherapy. So we assume that Kanglaite can reduce 3-4 degree mucositis from 50% to 30%.&#xD;
      The sample size required 44 cases according to the superiority test, bilateral Class I error&#xD;
      α = 0.05, class II error β = 0.2. Total 49 cases are need, assuming the off rate of 10%.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Actual">February 1, 2021</completion_date>
  <primary_completion_date type="Actual">February 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Kanglaite injection + Radiotherapy ± Chemotherapy</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the Incidence Rate of Severe Radiation Mucositis</measure>
    <time_frame>From date of randomization until the end radiotherapy, up to 3 months.</time_frame>
    <description>The grade of radiation mucositis was assessed by CTCAE v4. The highest grade be recorded. The grade 1 was the best and grade 4 was the worst.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the Incidence Rate of Non-Hematologic Toxicity Side Events</measure>
    <time_frame>From date of randomization until the end radiotherapy, up to 3 months.</time_frame>
    <description>The non-hematologic toxicity side events were assessed by CTCAE v4. The highest grade be recorded. The grade 1 was the best and grade 4 was the worst.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Incidence Rate of Hematologic Toxicity Side Events</measure>
    <time_frame>From date of randomization until the end radiotherapy, up to 3 months.</time_frame>
    <description>The grade of hematologic toxicity side events were assessed by CTCAE v4. The highest grade be recorded. The grade 1 was the best and grade 4 was the worst.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Nutritional Status</measure>
    <time_frame>From date of randomization until the end radiotherapy, up to 3 months.</time_frame>
    <description>The nutritional status was assessed by PG-SGA questionnaire.PG-SGA scores were recorded weekly during radiotherapy. A score of 0-1 indicated good nourishment, 2-8 suspected or moderate malnutrition, ≥ 9 risk of severe malnutrition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Overall Quality of Life (QOL)</measure>
    <time_frame>From date of randomization until the end radiotherapy, up to 3 months.</time_frame>
    <description>The overall quality of life was assessed by EORTC QLQ-C30 questionnaire. QLQ-C30 scores were valued weekly during radiotherapy and post radiotherapy.The worst score of patients was recorded. The QLQ-C30 was scored from 0 to 100. Higher scores for function indicated a better QOL whereas the symptoms indicated a worsening QOL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Specific to Head and Neck Cancers</measure>
    <time_frame>From date of randomization until the end radiotherapy, up to 3 months.</time_frame>
    <description>Quality of life specific to head and neck cancers was assessed by EORTC QLQ-H&amp;N35 questionnaire. QLQ-H&amp;N35 scores were valued weekly during radiotherapy and post radiotherapy. The highest score of patients was recorded. The QLQ-H&amp;N35 was scored from 0 to 100. Higher scores indicated a worsening QOL.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Head and Neck Cancer</condition>
  <condition>Radiotherapy</condition>
  <arm_group>
    <arm_group_label>Kanglaite group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Kanglaite 200ml is injected once a day from Monday to Friday during radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kanglaite</intervention_name>
    <description>Kanglaite injection 200ml is injected intravenous from the first day to the last day of radiotherapy.</description>
    <arm_group_label>Kanglaite group</arm_group_label>
    <other_name>Kanglaite injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
    <description>Cisplatin 80-100mg/m2 was used every 3 weeks during radiotherapy.</description>
    <arm_group_label>Kanglaite group</arm_group_label>
    <other_name>Concurrent chemotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18-80 years old, expected survival period ≥ 12 months&#xD;
&#xD;
          2. Karnofsky score ≥80 points&#xD;
&#xD;
          3. Pathological confirmed head and neck malignant tumors (oral, oropharynx, hypopharynx,&#xD;
             throat, nasopharynx, nasal paranasal sinus or other), radical radiotherapy (±&#xD;
             chemotherapy) or postoperative radiotherapy (± chemotherapy), radiotherapy dose 60&#xD;
             -70Gy&#xD;
&#xD;
          4. with or without induction chemotherapy (induced chemotherapy ≤ 3 cycles);&#xD;
&#xD;
          5. Meet the following laboratory diagnostic indicators:&#xD;
&#xD;
             Hemoglobin ≥120g / L, white blood cells 4.0-10.0 × 109 / L, neutrophils 2.0-7.5 × 109&#xD;
             / L, platelets 100-300 × 109 / L; creatinine ≤ normal upper limit (UNL); ALT and AST ≤&#xD;
             2.5 × UNL, alkaline phosphatase (ALP) ≤ 5 × UNL, total bilirubin (Tbil) ≤ UNL&#xD;
&#xD;
          6. Sign informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Distant metastases&#xD;
&#xD;
          2. Allergy to Kanglaite&#xD;
&#xD;
          3. Head and neck had previously received radiation therapy&#xD;
&#xD;
          4. Pregnancy or lactation patients&#xD;
&#xD;
          5. Targeted drug therapy during radiotherapy&#xD;
&#xD;
          6. Radio-chemotherapy uses cytotoxic drugs other than platinum&#xD;
&#xD;
          7. Currently active infections, or combined with rheumatic immune diseases, long-term&#xD;
             chronic infection, acute infection, inflammatory state; hematopoietic dysfunction of&#xD;
             the blood system diseases; severe cardiopulmonary disease&#xD;
&#xD;
          8. Mental history, can not cooperate with the treatment&#xD;
&#xD;
          9. Researchers believe unsuitable to participate in this trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhi-Ping Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital of Harbin Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>First Affiliated Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.cnki.net/KCMS/detail/detail.aspx?QueryID=1&amp;CurRec=1&amp;filename=YWLC201311028&amp;dbname=CJFD2013&amp;dbcode=CJFQ&amp;pr=&amp;urlid=&amp;yx=&amp;uid=WEEvREcwSlJHSldRa1FhdkJkcGkzcVBMVDlLcXRDRGlQd3hhNzRBZkFjbz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!&amp;v=MTgzNDJDVVJMMmZaT1J2Rml6Z1ViN0FQRHJIYmJHNEg5TE5ybzlIYklSOGVYMUx1eFlTN0RoMVQzcVRyV00xRnI=</url>
    <description>Jing JL, Li XL, Nan YQ. Advances in the study of the effect of Kanglaite injection on tumor therapy. Chinese Remedies &amp; Clinics, 2013;13(11):1447-1448 (in Chinese).</description>
  </link>
  <link>
    <url>http://www.cnki.net/KCMS/detail/detail.aspx?QueryID=6&amp;CurRec=1&amp;filename=XDYD199806032&amp;dbname=CJFD9899&amp;dbcode=CJFQ&amp;pr=&amp;urlid=&amp;yx=&amp;uid=WEEvREcwSlJHSldRa1FhdkJkcGkzcVBMVDlLcXRDRGlQd3hhNzRBZkFjbz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!&amp;v=MjczNDlPUnZGaXpnVkx6QVBTblNhckt4RjluTXFZOUdab1I4ZVgxTHV4WVM3RGgxVDNxVHJXTTFGckNVUkwyZlo=</url>
    <description>Guo Y, Li DP. Protective effects of Kanglaite injection on hematopoiesis and liver and kidney damage caused by three anticancer drugs. Chinese journal of modern applied phaemacy.1998;15(6):61-62(in Chinese).</description>
  </link>
  <link>
    <url>http://www.cnki.net/KCMS/detail/detail.aspx?QueryID=0&amp;CurRec=1&amp;filename=QLZL200306029&amp;dbname=CJFD2003&amp;dbcode=CJFQ&amp;pr=&amp;urlid=&amp;yx=&amp;uid=WEEvREcwSlJHSldRa1FhdkJkcGkzcVBMVDlLcXRDRGlQd3hhNzRBZkFjbz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!&amp;v=MDkyNDc0SHRMTXFZOUhiWVI4ZVgxTHV4WVM3RGgxVDNxVHJXTTFGckNVUkwyZlpPUnZGaS9rVnIvSk5DSFJZckc=</url>
    <description>Wang WD, Sun SP, Wang XD. Influence of KLT on Radiotherapy Effect of Patients with Advanced Nasopharyngeal Carcinoma. China Journal of Cancer Prevention and Treatment,2003:10(6): 635-637(in Chinese).</description>
  </link>
  <link>
    <url>http://www.cnki.net/KCMS/detail/detail.aspx?QueryID=0&amp;CurRec=1&amp;filename=XYJH200506008&amp;dbname=CJFD2005&amp;dbcode=CJFQ&amp;pr=&amp;urlid=&amp;yx=&amp;uid=WEEvREcwSlJHSldRa1FhdkJkcGkzcVBMVDlLcXRDRGlQd3hhNzRBZkFjbz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!&amp;v=MDM5ODBlWDFMdXhZUzdEaDFUM3FUcldNMUZyQ1VSTDJmWk9SdkZpL2xWYnZBUFRUQlpyRzRIdFRNcVk5RmJJUjg=</url>
    <description>Ren ZP, et al. The therapeutic effects of the combined therapy with kanglaite injection and radiotherapy on nasopharyngea carcinoma among aged cases. Chinese Journal of Otorhinolaryngology of Integrated Traditional and Western Medici 2005;13(6)</description>
  </link>
  <reference>
    <citation>Trotti A, Bellm LA, Epstein JB, Frame D, Fuchs HJ, Gwede CK, Komaroff E, Nalysnyk L, Zilberberg MD. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol. 2003 Mar;66(3):253-62. Review.</citation>
    <PMID>12742264</PMID>
  </reference>
  <reference>
    <citation>Redding SW. Cancer therapy-related oral mucositis. J Dent Educ. 2005 Aug;69(8):919-29.</citation>
    <PMID>16081575</PMID>
  </reference>
  <reference>
    <citation>Silverman S Jr. Diagnosis and management of oral mucositis. J Support Oncol. 2007 Feb;5(2 Suppl 1):13-21. Review.</citation>
    <PMID>17366929</PMID>
  </reference>
  <reference>
    <citation>Harris DJ. Cancer treatment-induced mucositis pain: strategies for assessment and management. Ther Clin Risk Manag. 2006 Sep;2(3):251-8.</citation>
    <PMID>18360600</PMID>
  </reference>
  <reference>
    <citation>Rodríguez-Caballero A, Torres-Lagares D, Robles-García M, Pachón-Ibáñez J, González-Padilla D, Gutiérrez-Pérez JL. Cancer treatment-induced oral mucositis: a critical review. Int J Oral Maxillofac Surg. 2012 Feb;41(2):225-38. doi: 10.1016/j.ijom.2011.10.011. Epub 2011 Nov 8. Review.</citation>
    <PMID>22071451</PMID>
  </reference>
  <reference>
    <citation>Walsh L, Gillham C, Dunne M, Fraser I, Hollywood D, Armstrong J, Thirion P. Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC). Radiother Oncol. 2011 Jan;98(1):38-41. doi: 10.1016/j.radonc.2010.11.009. Epub 2010 Dec 13.</citation>
    <PMID>21159400</PMID>
  </reference>
  <reference>
    <citation>Chen Y, Liu MZ, Liang SB, Zong JF, Mao YP, Tang LL, Guo Y, Lin AH, Zeng XF, Ma J. Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of china. Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1356-64. doi: 10.1016/j.ijrobp.2007.12.028. Epub 2008 May 9.</citation>
    <PMID>18472356</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 20, 2017</study_first_submitted>
  <study_first_submitted_qc>March 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2017</study_first_posted>
  <results_first_submitted>February 17, 2021</results_first_submitted>
  <results_first_submitted_qc>May 31, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 23, 2021</results_first_posted>
  <last_update_submitted>May 31, 2021</last_update_submitted>
  <last_update_submitted_qc>May 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>head and neck</keyword>
  <keyword>tumor</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>mucositis</keyword>
  <keyword>toxicity</keyword>
  <keyword>Kanglaite injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The investigators have no other clinical trial about cancer of head and neck</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 6, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT03101514/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>We recruited patients with head and neck cancer receiving radiotherapy in the First Affiliated Hospital of Harbin Medical University between January 2017 and October 2019.</recruitment_details>
      <pre_assignment_details>Sixty-two patients were assessed for eligibility. Three patients did not meet the inclusion criteria, and six patients declined to participate.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Kanglaite Group</title>
          <description>All patients received 20 g Kanglaite (200 mL) daily, administered as an intravenous injection for 5 days a week, concurrently with radiotherapy. Kanglaite injection was used before or after radiotherapy. There is no time interval requirement between Kanglaite and radiotherapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>patient's information was incomplete</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Kanglaite Group</title>
          <description>Kanglaite injection was used during radiotherapy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nutritional status</title>
          <description>Nutritional status was scored using Patient-Generated Subjective Global Assessment (PG-SGA) questionnaire.A score of 0-1 indicated good nourishment, a score of 2-8 indicated suspected or moderate malnutrition, and a score ≥ 9 indicated risk of severe malnutrition.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Severe malnutrition</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suspected or moderate malnutrition</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good nourishment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Quality of life specific to head and neck cancers</title>
          <description>Quality of life specific to head and neck cancers was assessed by EORTC-QLQ-H&amp;N35 questionnaires. Each item of the QLQ-H&amp;N35 was scored from 0 to 100. Higher scores indicated a worsening quality of life.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>pain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.22" spread="25.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>swallowing</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.62" spread="24.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sensory problems</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.25" spread="22.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>speech problems</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.67" spread="29.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>social eating problems</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.43" spread="25.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>social contact problems</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.48" spread="19.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>less sexuality</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.55" spread="30.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>teeth</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.44" spread="32.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mouth opening problem</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.58" spread="24.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>dry mouth</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.22" spread="26.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sticky saliva</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.36" spread="31.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>coughing</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.22" spread="28.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>feeling ill</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.22" spread="27.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Overall quality of life (QOL)</title>
          <description>Overall quality of life was assessed by EORTC-QLQ-C30 questionnaires.Each item of the QLQ-C30 was scored from 0 to 100. Higher scores for function on the QLQ-C30 (global QOL, physical functioning, role functioning, emotional functioning, cognitive functioning, social functioning) indicated a better QOL, whereas higher scores for the symptoms on the QLQ-C30 (fatigue, nausea and vomiting, pain, dyspnoea,insomnia, appetite loss,constipation, diarrhoea) indicated a worsening QOL</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>global QOL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.18" spread="25.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>physical functioning</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89.99" spread="12.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>role functioning</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82.6" spread="24.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>emotional functioning</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84.48" spread="18.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cognitive functioning</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81.46" spread="25.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>social functioning</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.1" spread="30.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>fatigue</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.40" spread="19.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>nausea and vomiting</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.07" spread="12.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.3" spread="19.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>dyspnoea</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.59" spread="22.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>insomnia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.07" spread="27.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>appetite loss</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.81" spread="25.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>constipation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.36" spread="21.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>diarrhoea</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.88" spread="16.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>the Incidence Rate of Severe Radiation Mucositis</title>
        <description>The grade of radiation mucositis was assessed by CTCAE v4. The highest grade be recorded. The grade 1 was the best and grade 4 was the worst.</description>
        <time_frame>From date of randomization until the end radiotherapy, up to 3 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kanglaite Group</title>
            <description>Kanglaite 200ml is injected once a day from Monday to Friday during radiotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>the Incidence Rate of Severe Radiation Mucositis</title>
          <description>The grade of radiation mucositis was assessed by CTCAE v4. The highest grade be recorded. The grade 1 was the best and grade 4 was the worst.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 1 mucositis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 mucositis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 mucositis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4 mucositis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>the Incidence Rate of Non-Hematologic Toxicity Side Events</title>
        <description>The non-hematologic toxicity side events were assessed by CTCAE v4. The highest grade be recorded. The grade 1 was the best and grade 4 was the worst.</description>
        <time_frame>From date of randomization until the end radiotherapy, up to 3 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kanglaite Group</title>
            <description>Kanglaite 200ml is injected once a day from Monday to Friday during radiotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>the Incidence Rate of Non-Hematologic Toxicity Side Events</title>
          <description>The non-hematologic toxicity side events were assessed by CTCAE v4. The highest grade be recorded. The grade 1 was the best and grade 4 was the worst.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>grade 1 superficial phlebitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>grade 1 rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>radiotherapy dose reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>irradiation field modification</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>radiotherapy interruption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>the Incidence Rate of Hematologic Toxicity Side Events</title>
        <description>The grade of hematologic toxicity side events were assessed by CTCAE v4. The highest grade be recorded. The grade 1 was the best and grade 4 was the worst.</description>
        <time_frame>From date of randomization until the end radiotherapy, up to 3 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kanglaite Group</title>
            <description>Kanglaite 200ml is injected once a day from Monday to Friday during radiotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>the Incidence Rate of Hematologic Toxicity Side Events</title>
          <description>The grade of hematologic toxicity side events were assessed by CTCAE v4. The highest grade be recorded. The grade 1 was the best and grade 4 was the worst.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Neutropenia</title>
              <category_list>
                <category>
                  <title>grade 0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>grade 1-2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>grade 3-4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anemia</title>
              <category_list>
                <category>
                  <title>grade 0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>grade 1-2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>grade 3-4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombocytopenia</title>
              <category_list>
                <category>
                  <title>grade 0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>grade 1-2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>grade 3-4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-albumin decrease</title>
              <category_list>
                <category>
                  <title>grade 0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>grade 1-2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>grade 3-4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin decreasing</title>
              <category_list>
                <category>
                  <title>grade 0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>grade 1-2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>grade 3-4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>alanine transaminase increasing</title>
              <category_list>
                <category>
                  <title>grade 0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>grade 1-2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>grade 3-4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>aspartate transaminase increasing</title>
              <category_list>
                <category>
                  <title>grade 0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>grade 1-2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>grade 3-4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>alkaline phosphatase increasing</title>
              <category_list>
                <category>
                  <title>grade 0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>grade 1-2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>grade 3-4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total bilirubin increasing</title>
              <category_list>
                <category>
                  <title>grade 0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>grade 1-2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>grade 3-4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>creatinine increasing</title>
              <category_list>
                <category>
                  <title>grade 0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>grade 1-2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>grade 3-4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>blood urea nitrogen increasing</title>
              <category_list>
                <category>
                  <title>grade 0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>grade 1-2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>grade 3-4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>the Nutritional Status</title>
        <description>The nutritional status was assessed by PG-SGA questionnaire.PG-SGA scores were recorded weekly during radiotherapy. A score of 0-1 indicated good nourishment, 2-8 suspected or moderate malnutrition, ≥ 9 risk of severe malnutrition.</description>
        <time_frame>From date of randomization until the end radiotherapy, up to 3 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kanglaite Group</title>
            <description>Kanglaite 200ml is injected once a day from Monday to Friday during radiotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>the Nutritional Status</title>
          <description>The nutritional status was assessed by PG-SGA questionnaire.PG-SGA scores were recorded weekly during radiotherapy. A score of 0-1 indicated good nourishment, 2-8 suspected or moderate malnutrition, ≥ 9 risk of severe malnutrition.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Score 0-1</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Score 2-8</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Score ≧9</title>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>the Overall Quality of Life (QOL)</title>
        <description>The overall quality of life was assessed by EORTC QLQ-C30 questionnaire. QLQ-C30 scores were valued weekly during radiotherapy and post radiotherapy.The worst score of patients was recorded. The QLQ-C30 was scored from 0 to 100. Higher scores for function indicated a better QOL whereas the symptoms indicated a worsening QOL.</description>
        <time_frame>From date of randomization until the end radiotherapy, up to 3 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kanglaite Group</title>
            <description>Kanglaite 200ml is injected once a day from Monday to Friday during radiotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>the Overall Quality of Life (QOL)</title>
          <description>The overall quality of life was assessed by EORTC QLQ-C30 questionnaire. QLQ-C30 scores were valued weekly during radiotherapy and post radiotherapy.The worst score of patients was recorded. The QLQ-C30 was scored from 0 to 100. Higher scores for function indicated a better QOL whereas the symptoms indicated a worsening QOL.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>global quality of life during radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.52" spread="29.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>physical functioning during radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.19" spread="21.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rolel functioning during radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.28" spread="27.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>emotional functioning during radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.35" spread="22.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cognitive functioning during radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.99" spread="23.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>social functioning during radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.68" spread="31.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>fatigue during radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.32" spread="21.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>nausea and vomiting during radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.07" spread="24.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pain during radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.05" spread="26.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>dyspnoea during radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.01" spread="28.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>insomnia during radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.15" spread="31.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>appetite loss during radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.47" spread="32.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>costipation during radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.08" spread="28.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>diarrhoea during radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.31" spread="19.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>global quality of life post radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.72" spread="24.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>physical functioning post radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.09" spread="22.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>role functioning post radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.58" spread="25.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>emotional functioning post radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4" spread="10.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cognitive functioning post radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.72" spread="20.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>social functioning post radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.09" spread="27.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>fatigue post radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.16" spread="23.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>nausea and vomiting post radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.26" spread="19.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pain post radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.70" spread="23.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>dyspnoea post radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.12" spread="31.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>insomnia post radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.70" spread="30.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>appetite post radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.53" spread="30.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>constipation post radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.27" spread="23.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>diarrhoea post radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.65" spread="11.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Specific to Head and Neck Cancers</title>
        <description>Quality of life specific to head and neck cancers was assessed by EORTC QLQ-H&amp;N35 questionnaire. QLQ-H&amp;N35 scores were valued weekly during radiotherapy and post radiotherapy. The highest score of patients was recorded. The QLQ-H&amp;N35 was scored from 0 to 100. Higher scores indicated a worsening QOL.</description>
        <time_frame>From date of randomization until the end radiotherapy, up to 3 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kanglaite Group</title>
            <description>Kanglaite 200ml is injected once a day from Monday to Friday during radiotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Specific to Head and Neck Cancers</title>
          <description>Quality of life specific to head and neck cancers was assessed by EORTC QLQ-H&amp;N35 questionnaire. QLQ-H&amp;N35 scores were valued weekly during radiotherapy and post radiotherapy. The highest score of patients was recorded. The QLQ-H&amp;N35 was scored from 0 to 100. Higher scores indicated a worsening QOL.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>pain during radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.83" spread="23.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>swallowing during radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.03" spread="27.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sensory problems during radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.5" spread="26.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>speech problems during radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.59" spread="36.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>social eating problems during radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.57" spread="30.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>social contact problems during radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.08" spread="25.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>less sexuality during radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.86" spread="40.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>teeth during radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.98" spread="34.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mouth opening problems during radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.53" spread="28.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>dry mouth during radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.14" spread="29.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sticky saliva during radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.66" spread="26.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>coughing during radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.75" spread="33.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>feeling ill during radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.40" spread="27.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pain post radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.72" spread="26.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>swallowing post radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.04" spread="23.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sensory problems post radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.04" spread="29.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>speech problems post radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.49" spread="35.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>social eating problems post radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.09" spread="24.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>social contact problems post radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.99" spread="17.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>less sexuality post radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.96" spread="38.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>teeth post radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.25" spread="29.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mouth opening problems post radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.40" spread="17.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>dry mouth post radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.48" spread="34.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sticky saliva post radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.58" spread="35.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>coughing post radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.2" spread="33.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>feeling ill post radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.20" spread="29.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Kanglaite Group</title>
          <description>Kanglaite 200ml is injected once a day from Monday to Friday during radiotherapy.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>mucositis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pre-albumin</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Glutamic oxaloacetic transaminase</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Total bilirubin</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Zhi-Ping Liu</name_or_title>
      <organization>the first affiliated hospital of Harbin medical university</organization>
      <phone>+8613936034546</phone>
      <email>as150001@aliyun.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

